Yoshida K, et al. - In order to verify that postoperative S-1 (a standard postoperative adjuvant chemotherapy) plus docetaxel is superior to S-1 alone for R0 resection of pathologic stage III gastric cancer, researchers performed this randomized phase 3 study with a primary end point defined as a 7% increment in 3-year relapse-free survival, for which 1,100 patients were required. As for 3-year relapse-free survival, S-1 plus docetaxel (66%) was found superior to S-1 (50%) in this study. Overall, few safety concerns were seen with the addition of docetaxel to S-1, which proved an effective treatment strategy in patients with stage III gastric cancer. It may be justified to apply these results in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard.